PL2049475T3 - Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1 - Google Patents

Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1

Info

Publication number
PL2049475T3
PL2049475T3 PL07761153T PL07761153T PL2049475T3 PL 2049475 T3 PL2049475 T3 PL 2049475T3 PL 07761153 T PL07761153 T PL 07761153T PL 07761153 T PL07761153 T PL 07761153T PL 2049475 T3 PL2049475 T3 PL 2049475T3
Authority
PL
Poland
Prior art keywords
inhibitors
beta
compounds
hydroxysteroid dehydrogenase
cyclohexyl substituted
Prior art date
Application number
PL07761153T
Other languages
English (en)
Inventor
Alexei Pavlovych Krasutsky
Nancy June Snyder
Owen Brendan Wallace
Yanping Xu
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2049475T3 publication Critical patent/PL2049475T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
PL07761153T 2006-04-24 2007-04-24 Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1 PL2049475T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74544206P 2006-04-24 2006-04-24
EP07761153A EP2049475B1 (en) 2006-04-24 2007-04-24 Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PCT/US2007/067253 WO2007127704A1 (en) 2006-04-24 2007-04-24 Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Publications (1)

Publication Number Publication Date
PL2049475T3 true PL2049475T3 (pl) 2012-08-31

Family

ID=38374154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07761153T PL2049475T3 (pl) 2006-04-24 2007-04-24 Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1

Country Status (17)

Country Link
US (1) US7998999B2 (pl)
EP (1) EP2049475B1 (pl)
JP (1) JP5118692B2 (pl)
CN (1) CN101432262B (pl)
AT (1) ATE543798T1 (pl)
AU (1) AU2007244971B2 (pl)
BR (1) BRPI0710468A2 (pl)
CA (1) CA2649111C (pl)
CY (1) CY1112398T1 (pl)
DK (1) DK2049475T3 (pl)
EA (1) EA016415B1 (pl)
ES (1) ES2378574T3 (pl)
MX (1) MX2008013658A (pl)
PL (1) PL2049475T3 (pl)
PT (1) PT2049475E (pl)
SI (1) SI2049475T1 (pl)
WO (1) WO2007127704A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647677C (en) * 2006-04-21 2014-03-18 Eli Lilly And Company Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0710273A2 (pt) 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
ES2435115T3 (es) 2006-04-21 2013-12-18 Eli Lilly And Company Derivados de bifenilamida-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
AU2007244955B2 (en) * 2006-04-24 2011-12-08 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244960B2 (en) 2006-04-24 2012-03-01 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2016071B1 (en) 2006-04-25 2013-07-24 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101432265B (zh) 2006-04-25 2011-12-14 伊莱利利公司 11-β-羟类固醇脱氢酶1的抑制剂
EP2021337B1 (en) 2006-04-25 2010-01-13 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US7829582B2 (en) * 2006-04-28 2010-11-09 Eli Lilly And Company Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018014337A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
RU2741910C2 (ru) * 2019-07-09 2021-01-29 Государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации Соединения, обладающие антиишемическими, антиангинальными, цитопротективными свойствами, способ их получения и их применение, способ лечения нейродегенеративного заболевания, способ лечения психического расстройства

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
ES2130428T3 (es) 1993-06-21 1999-07-01 Novo Nordisk As Cristales de insulina asp-b28.
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
PL369108A1 (pl) * 2001-09-06 2005-04-18 Schering Corporation Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7687644B2 (en) * 2004-05-07 2010-03-30 Janssen Pharmaceutica Nv Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
AU2005240784C1 (en) * 2004-05-07 2011-12-22 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
SI1807072T1 (sl) 2004-10-29 2009-06-30 Lilly Co Eli Derivati cikloalkil laktamov kot inhibitorji 11-beta-hidroksisteroid dehidrogenaze 1
CA2585797C (en) 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
ES2308602T3 (es) 2004-12-20 2008-12-01 Eli Lilly And Company Derivados de cicloalquil lactamas como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa 1.
ATE401073T1 (de) 2004-12-21 2008-08-15 Lilly Co Eli Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
EP1864971A4 (en) 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
ES2435115T3 (es) 2006-04-21 2013-12-18 Eli Lilly And Company Derivados de bifenilamida-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BRPI0710273A2 (pt) 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
CA2647677C (en) 2006-04-21 2014-03-18 Eli Lilly And Company Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244960B2 (en) 2006-04-24 2012-03-01 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244955B2 (en) 2006-04-24 2011-12-08 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2016071B1 (en) 2006-04-25 2013-07-24 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2021337B1 (en) 2006-04-25 2010-01-13 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101432265B (zh) 2006-04-25 2011-12-14 伊莱利利公司 11-β-羟类固醇脱氢酶1的抑制剂
US7829582B2 (en) 2006-04-28 2010-11-09 Eli Lilly And Company Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

Also Published As

Publication number Publication date
CY1112398T1 (el) 2015-12-09
DK2049475T3 (da) 2012-03-05
SI2049475T1 (sl) 2012-04-30
AU2007244971A1 (en) 2007-11-08
MX2008013658A (es) 2008-11-04
EA200870472A1 (ru) 2009-06-30
US7998999B2 (en) 2011-08-16
ATE543798T1 (de) 2012-02-15
EA016415B1 (ru) 2012-04-30
EP2049475B1 (en) 2012-02-01
WO2007127704A1 (en) 2007-11-08
JP2009534471A (ja) 2009-09-24
CN101432262B (zh) 2011-06-01
ES2378574T3 (es) 2012-04-16
EP2049475A1 (en) 2009-04-22
CA2649111A1 (en) 2007-11-08
JP5118692B2 (ja) 2013-01-16
BRPI0710468A2 (pt) 2011-08-16
CA2649111C (en) 2013-09-10
CN101432262A (zh) 2009-05-13
PT2049475E (pt) 2012-04-12
US20090239911A1 (en) 2009-09-24
AU2007244971B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
PL2049475T3 (pl) Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
IL194879A0 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2029529T3 (pl) PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1
UA95798C2 (ru) Производные циклогексилпиразоллактама как ингибиторы 11-бета-гидроксистероиддегидрогеназы 1
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
PL2021337T3 (pl) Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
MY148079A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL1807072T3 (pl) Cykloalkilowe pochodne laktamów jako inhibitory 11-ß-HSD1